{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:48:34Z","timestamp":1781876914185,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974001"],"award-info":[{"award-number":["81974001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170222"],"award-info":[{"award-number":["82170222"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211070"],"award-info":[{"award-number":["BK20211070"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Key Disease Program of Suzhou","award":["LCZX202101"],"award-info":[{"award-number":["LCZX202101"]}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2017ZX09304021"],"award-info":[{"award-number":["2017ZX09304021"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2019YFC0840604"],"award-info":[{"award-number":["2019YFC0840604"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2017YFA0104502"],"award-info":[{"award-number":["2017YFA0104502"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Key Medical Center","award":["YXZXA2016002"],"award-info":[{"award-number":["YXZXA2016002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00277-024-05791-z","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:02:08Z","timestamp":1715947328000},"page":"2463-2473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Tong","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-0631","authenticated-orcid":false,"given":"Xiaojin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"5791_CR1","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood.V128.22.4004","volume":"128","author":"Y Choi","year":"2016","unstructured":"Choi Y, Lee J-H, Lee K-H et al (2016) Treatment outcomes and prognostic factors of patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 128:4004. https:\/\/doi.org\/10.1182\/blood.V128.22.4004","journal-title":"Blood"},{"key":"5791_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98:502\u2013526. https:\/\/doi.org\/10.1002\/ajh.26822","journal-title":"Am J Hematol"},{"key":"5791_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/1042819021000054670","volume":"44","author":"KU Chow","year":"2003","unstructured":"Chow KU, Boehrer S, Napieralski S et al (2003) In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 44:165\u2013173. https:\/\/doi.org\/10.1080\/1042819021000054670","journal-title":"Leuk Lymphoma"},{"key":"5791_CR4","doi-asserted-by":"publisher","first-page":"106300","DOI":"10.1016\/j.leukres.2020.106300","volume":"90","author":"CJ Scheckel","year":"2020","unstructured":"Scheckel CJ, Meyer M, Betcher JA et al (2020) Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after \u201cCLAG-M\u201d vs. \u201cMEC.\u201d Leuk Res 90:106300. https:\/\/doi.org\/10.1016\/j.leukres.2020.106300","journal-title":"Leuk Res"},{"key":"5791_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood.V87.1.256.256","volume":"87","author":"V Gandhi","year":"1996","unstructured":"Gandhi V, Estey E, Keating MJ et al (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256\u2013264","journal-title":"Blood"},{"key":"5791_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-11-126227","volume":"112","author":"H Kroeger","year":"2008","unstructured":"Kroeger H, Jelinek J, Est\u00e9cio MR et al (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:1366\u20131373. https:\/\/doi.org\/10.1182\/blood-2007-11-126227","journal-title":"Blood"},{"key":"5791_CR7","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/s2352-3026(18)30132-7","volume":"5","author":"TM Kadia","year":"2018","unstructured":"Kadia TM, Cortes J, Ravandi F et al (2018) Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5:e411\u2013e421. https:\/\/doi.org\/10.1016\/s2352-3026(18)30132-7","journal-title":"Lancet Haematol"},{"key":"5791_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-005-1046-0","volume":"84","author":"A Wrzesie\u0144-Ku\u015b","year":"2005","unstructured":"Wrzesie\u0144-Ku\u015b A, Robak T, Wierzbowska A et al (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 84:557\u2013564. https:\/\/doi.org\/10.1007\/s00277-005-1046-0","journal-title":"Ann Hematol"},{"key":"5791_CR9","doi-asserted-by":"publisher","first-page":"e1663","DOI":"10.1634\/theoncologist.2020-0818","volume":"25","author":"H Wang","year":"2020","unstructured":"Wang H, Wang L, Li C et al (2020) Cladribine with granulocyte colony-stimulating factor, cytarabine, and aclarubicin regimen in refractory\/relapsed acute myeloid leukemia: a phase II multicenter study. Oncologist 25:e1663\u2013e1670. https:\/\/doi.org\/10.1634\/theoncologist.2020-0818","journal-title":"Oncologist"},{"key":"5791_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2022-159962","volume":"140","author":"M Stelljes","year":"2022","unstructured":"Stelljes M, Middeke JM, Bug G et al (2022) In patients with relapsed\/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: results from the randomized phase III ASAP trial. Blood 140:9\u201311. https:\/\/doi.org\/10.1182\/blood-2022-159962","journal-title":"Blood"},{"key":"5791_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2019001982","volume":"136","author":"S DeWolf","year":"2020","unstructured":"DeWolf S, Tallman MS (2020) How I treat relapsed or refractory AML. Blood 136:1023\u20131032. https:\/\/doi.org\/10.1182\/blood.2019001982","journal-title":"Blood"},{"key":"5791_CR12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.6004\/jnccn.2012.0103","volume":"10","author":"MR O'Donnell","year":"2012","unstructured":"O\u2019Donnell MR, Abboud CN, Altman J et al (2012) NCCN Clinical Practice Guidelines Acute myeloid leukemia. J Natl Compr Canc Netw 10:984\u20131021. https:\/\/doi.org\/10.6004\/jnccn.2012.0103","journal-title":"J Natl Compr Canc Netw"},{"key":"5791_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131:1275\u20131291. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"5791_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko CL, Pidala J, Schoemans HM et al (2021) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report. Transplant Cell Ther 27:545\u2013557. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.033","journal-title":"Transplant Cell Ther"},{"key":"5791_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH et al (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64:87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"key":"5791_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2023","unstructured":"Soldan SS, Lieberman PM (2023) Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol 21:51\u201364. https:\/\/doi.org\/10.1038\/s41579-022-00770-5","journal-title":"Nat Rev Microbiol"},{"key":"5791_CR17","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825\u2013828","journal-title":"Bone Marrow Transplant"},{"key":"5791_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/nejm199004193221605","volume":"322","author":"LD Piro","year":"1990","unstructured":"Piro LD, Carrera CJ, Carson DA et al (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117\u20131121. https:\/\/doi.org\/10.1056\/nejm199004193221605","journal-title":"N Engl J Med"},{"key":"5791_CR19","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood.V130.Suppl_1.3898.3898","volume":"130","author":"P Boddu","year":"2017","unstructured":"Boddu P, Kantarjian HM, Ravandi F et al (2017) Outcomes by treatment setting and genomic profile in patients with AML on cladribine, idarubicin, and cytarabine. Blood 130:3898. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3898.3898","journal-title":"Blood"},{"key":"5791_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2015-08-662130","volume":"127","author":"M Libura","year":"2016","unstructured":"Libura M, Giebel S, Piatkowska-Jakubas B et al (2016) Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood 127:360\u2013362. https:\/\/doi.org\/10.1182\/blood-2015-08-662130","journal-title":"Blood"},{"key":"5791_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/10428194.2019.1672060","volume":"61","author":"M Molica","year":"2020","unstructured":"Molica M, Breccia M, Capria S et al (2020) The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leuk Lymphoma 61:536\u2013545. https:\/\/doi.org\/10.1080\/10428194.2019.1672060","journal-title":"Leuk Lymphoma"},{"key":"5791_CR22","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.clml.2017.09.016","volume":"18","author":"B Muluneh","year":"2018","unstructured":"Muluneh B, Buhlinger K, Deal AM et al (2018) A comparison of clofarabine-based (GCLAC) and cladribine-based (CLAG) salvage chemotherapy for relapsed\/refractory AML. Clin Lymphoma Myeloma Leuk 18:e13\u2013e18. https:\/\/doi.org\/10.1016\/j.clml.2017.09.016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5791_CR23","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O'Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN et al (2017) Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:926\u2013957. https:\/\/doi.org\/10.6004\/jnccn.2017.0116","journal-title":"J Natl Compr Canc Netw"},{"key":"5791_CR24","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.2147\/dddt.S207425","volume":"13","author":"A Zhou","year":"2019","unstructured":"Zhou A, Han Q, Song H et al (2019) Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis. Drug Des Devel Ther 13:1867\u20131878. https:\/\/doi.org\/10.2147\/dddt.S207425","journal-title":"Drug Des Devel Ther"},{"key":"5791_CR25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/cam4.3681","volume":"10","author":"M Ruan","year":"2021","unstructured":"Ruan M, Liu LP, Zhang AL et al (2021) Improved outcome of children with relapsed\/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy. Cancer Med 10:956\u2013964. https:\/\/doi.org\/10.1002\/cam4.3681","journal-title":"Cancer Med"},{"key":"5791_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ajh.23862","volume":"90","author":"CW Freyer","year":"2015","unstructured":"Freyer CW, Gupta N, Wetzler M et al (2015) Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol 90:62\u201372. https:\/\/doi.org\/10.1002\/ajh.23862","journal-title":"Am J Hematol"},{"key":"5791_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33595","author":"Y Hui","year":"2021","unstructured":"Hui Y, Li Y, Tong X et al (2021) Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: A preliminary study. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.33595","journal-title":"Int J Cancer"},{"key":"5791_CR28","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00277-019-03723-w","volume":"98","author":"P Ye","year":"2019","unstructured":"Ye P, Pei R, Jin J et al (2019) Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed\/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. Ann Hematol 98:2073\u20132080. https:\/\/doi.org\/10.1007\/s00277-019-03723-w","journal-title":"Ann Hematol"},{"key":"5791_CR29","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1182\/blood.v97.11.3405","volume":"97","author":"D Przepiorka","year":"2001","unstructured":"Przepiorka D, Smith TL, Folloder J et al (2001) Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 97:3405\u20133410. https:\/\/doi.org\/10.1182\/blood.v97.11.3405","journal-title":"Blood"},{"key":"5791_CR30","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212. https:\/\/doi.org\/10.1200\/jco.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"5791_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000010228","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang J, Zhao J, Fei X et al (2018) A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Medicine (Baltimore) 97:e0228. https:\/\/doi.org\/10.1097\/md.0000000000010228","journal-title":"Medicine (Baltimore)"},{"key":"5791_CR32","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1200\/jco.1995.13.9.2431","volume":"13","author":"BD Cheson","year":"1995","unstructured":"Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431\u20132448. https:\/\/doi.org\/10.1200\/jco.1995.13.9.2431","journal-title":"J Clin Oncol"},{"key":"5791_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/bjc.1993.24","volume":"67","author":"T Hickish","year":"1993","unstructured":"Hickish T, Serafinowski P, Cunningham D et al (1993) 2\u2019-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67:139\u2013143. https:\/\/doi.org\/10.1038\/bjc.1993.24","journal-title":"Br J Cancer"},{"key":"5791_CR34","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","volume":"116","author":"DS Sigal","year":"2010","unstructured":"Sigal DS, Miller HJ, Schram ED et al (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116:2884\u20132896. https:\/\/doi.org\/10.1182\/blood-2010-02-246140","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05791-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05791-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05791-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:07:13Z","timestamp":1720109233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05791-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5791"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05791-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols were approved by institutional review board of the First Affiliated Hospital of Soochow University and Soochow Hopes Hematonosis Hospital. Informed consents were obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}